Suppr超能文献

回顾性深入分析肝糖原贮积病患者的连续血糖监测数据集:葡萄糖管理的推荐结局参数。

A retrospective in-depth analysis of continuous glucose monitoring datasets for patients with hepatic glycogen storage disease: Recommended outcome parameters for glucose management.

机构信息

Section of Metabolic Diseases, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

enerGQ BV, Groningen, The Netherlands.

出版信息

J Inherit Metab Dis. 2021 Sep;44(5):1136-1150. doi: 10.1002/jimd.12383. Epub 2021 May 5.

Abstract

Continuous glucose monitoring (CGM) systems have great potential for real-time assessment of glycemic variation in patients with hepatic glycogen storage disease (GSD). However, detailed descriptions and in-depth analysis of CGM data from hepatic GSD patients during interventions are scarce. This is a retrospective in-depth analysis of CGM parameters, acquired in a continuous, real-time fashion describing glucose management in 15 individual GSD patients. CGM subsets are obtained both in-hospital and at home, upon nocturnal dietary intervention (n = 1), starch loads (n = 11) and treatment of GSD Ib patients with empagliflozin (n = 3). Descriptive CGM parameters, and parameters reflecting glycemic variation and glycemic control are considered useful CGM outcome parameters. Furthermore, the combination of first and second order derivatives, cumulative sum and Fourier analysis identified both subtle and sudden changes in glucose management; hence, aiding assessment of dietary and medical interventions. CGM data interpolation for nocturnal intervals reduced confounding by physical activity and diet. Based on these analyses, we conclude that in-depth CGM analysis can be a powerful tool to assess glucose management and optimize treatment in individual hepatic GSD patients.

摘要

连续血糖监测 (CGM) 系统在实时评估肝糖原贮积病 (GSD) 患者的血糖变化方面具有巨大潜力。然而,对于肝 GSD 患者在干预期间的 CGM 数据的详细描述和深入分析却很少。这是对 15 名 GSD 患者的 CGM 参数进行回顾性深入分析,以连续、实时的方式描述血糖管理。CGM 子集是在住院期间和在家中获得的,包括夜间饮食干预 (n=1)、淀粉负荷 (n=11) 和用恩格列净治疗 GSD Ib 患者 (n=3)。描述性 CGM 参数以及反映血糖变化和血糖控制的参数被认为是有用的 CGM 结果参数。此外,一阶和二阶导数、累积和傅里叶分析的组合可以识别出血糖管理中的细微和突然变化,从而有助于评估饮食和医疗干预措施。夜间间隔的 CGM 数据内插可减少运动和饮食带来的混杂因素。基于这些分析,我们得出结论,深入的 CGM 分析可以成为评估个体肝 GSD 患者血糖管理和优化治疗的有力工具。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2765/8519135/22851ae57d47/JIMD-44-1136-g002.jpg

相似文献

3
A Prospective Study on Continuous Glucose Monitoring in Glycogen Storage Disease Type Ia: Toward Glycemic Targets.
J Clin Endocrinol Metab. 2022 Aug 18;107(9):e3612-e3623. doi: 10.1210/clinem/dgac411.
4
[The application of continuous glucose monitoring in the management of hepatic glycogen storage disease].
Zhonghua Er Ke Za Zhi. 2021 Jun 2;59(6):452-458. doi: 10.3760/cma.j.cn112140-20210321-00235.
5
The use of continuous glucose monitoring in the practical management of glycogen storage disorders.
J Inherit Metab Dis. 2011 Jun;34(3):631-42. doi: 10.1007/s10545-011-9335-3. Epub 2011 May 10.
6
Continuous glucose monitoring in children with glycogen storage disease type I.
Eur J Clin Nutr. 2014 Jan;68(1):101-5. doi: 10.1038/ejcn.2013.186. Epub 2013 Oct 23.
7
Glycemic control and complications in glycogen storage disease type I: Results from the Swiss registry.
Mol Genet Metab. 2019 Apr;126(4):355-361. doi: 10.1016/j.ymgme.2019.02.008. Epub 2019 Feb 28.
10
Real-life utilization of real-time continuous glucose monitoring: the complete picture.
J Diabetes Sci Technol. 2011 Jul 1;5(4):860-70. doi: 10.1177/193229681100500407.

引用本文的文献

1
Placenta Pathologies in Two Patients With Glycogen Storage Disease Type Ia and Preeclampsia.
JIMD Rep. 2025 Jun 12;66(4):e70025. doi: 10.1002/jmd2.70025. eCollection 2025 Jul.
7
Continuous glucose monitoring in patients with inherited metabolic disorders at risk for Hypoglycemia and Nutritional implications.
Rev Endocr Metab Disord. 2024 Oct;25(5):897-910. doi: 10.1007/s11154-024-09903-y. Epub 2024 Oct 1.
9
Dapagliflozin and Empagliflozin in Paediatric Indications: A Systematic Review.
Paediatr Drugs. 2024 May;26(3):229-243. doi: 10.1007/s40272-024-00623-z. Epub 2024 Apr 18.
10
Endocrine involvement in hepatic glycogen storage diseases: pathophysiology and implications for care.
Rev Endocr Metab Disord. 2024 Aug;25(4):707-725. doi: 10.1007/s11154-024-09880-2. Epub 2024 Apr 1.

本文引用的文献

2
The multiple faces of urinary glucose tetrasaccharide as biomarker for patients with hepatic glycogen storage diseases.
Genet Med. 2020 Nov;22(11):1915-1916. doi: 10.1038/s41436-020-0878-2. Epub 2020 Jul 13.
4
A standard set of person-centred outcomes for diabetes mellitus: results of an international and unified approach.
Diabet Med. 2020 Dec;37(12):2009-2018. doi: 10.1111/dme.14286. Epub 2020 Mar 20.
5
Introduction: .
Diabetes Care. 2020 Jan;43(Suppl 1):S1-S2. doi: 10.2337/dc20-Sint.
6
7
A New Era for Rare Genetic Diseases: Messenger RNA Therapy.
Hum Gene Ther. 2019 Oct;30(10):1180-1189. doi: 10.1089/hum.2019.090. Epub 2019 Jul 1.
10
Glycemic control and complications in glycogen storage disease type I: Results from the Swiss registry.
Mol Genet Metab. 2019 Apr;126(4):355-361. doi: 10.1016/j.ymgme.2019.02.008. Epub 2019 Feb 28.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验